Rectal CarcinomaPhase 2NCT04205955
Testing Diet Intervention Versus Non-Diet Intervention for Management of Bowel Symptoms in Rectal Cancer Survivors
A Phase 2 study testing Best Practice, Dietary Intervention and Message in people with Rectal Carcinoma and Rectosigmoid Carcinoma, run by SWOG Cancer Research Network at 226 sites in 2 countries.
Trial summary
This phase II trial studies how a diet intervention works in improving bowel dysfunction symptoms related in colon or rectal cancer survivors. Changing a diet may be helpful in reducing the severity of bowel symptoms, including diarrhea and constipation, and improve quality of life in colon or rectal cancer survivors… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Rectal Carcinoma, Rectosigmoid Carcinoma
- What is being tested?
- Best Practice, Dietary Intervention and Message
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 95 participants
- Where
- 226 sitesin 2 countries
- Study dates
- 10 Feb 2020to 1 Aug 2023
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- PRIOR TO STEP 1 REGISTRATION:
- Patients must have prior history of rectosigmoid colon cancer or rectal cancer
- Patients must have a post-surgical permanent ostomy or anastomosis
- Patient's last date of treatment for rectal cancer (any surgery, chemotherapy, radiation therapy) must be at least 6 months prior to registration and not more than 24 months prior to registration
- Anastomosis patients must have low anterior resection syndrome (LARS) score of 21-42 (minor to major symptoms) within 5 calendar days prior to registration
- Patient must have completed all baseline questionnaires within 5 days prior to registration
Show all 16Show fewer
- Patients must be able to read, write and speak English. Study materials and telephone calls are only available in English
- Patients with a prior malignancy or concurrent malignancy that is currently not being treated, whose natural history or treatment (in the opinion of the treating physician) does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- Patients who are currently undergoing treatment for another cancer will have a different symptom profile than what this study is targeting and are not eligible
- Patients who have been diagnosed with inflammatory bowel disease (IBD), such as ulcerative colitis or Crohn's disease, are not eligible
- PRIOR TO STEP 2 REGISTRATION:
- Patient must meet all eligibility criteria for step 1
- Patient must have successfully completed ("pass") the run-in period, as per email notification from the University of Arizona
- Patient must be registered to step 2 no more than 40 days after step 1 registration. If day 40 falls on a weekend or holiday, the limit may be extended to the next working day
- Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
- As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
Who cannot join
None listed.
Trial locations and contacts
226 sites in 2 countries.
226 sites in 2 countries
United States225 sites
Hawaii Cancer Care - Savio
‘Aiea, Hawaii, 96701
Pali Momi Medical Center
‘Aiea, Hawaii, 96701
Queen's Cancer Center - Pearlridge
‘Aiea, Hawaii, 96701
The Cancer Center of Hawaii-Pali Momi
‘Aiea, Hawaii, 96701
Lovelace Medical Center-Saint Joseph Square
Albuquerque, New Mexico, 87102
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87102
Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania, 18103
Mary Greeley Medical Center
Ames, Iowa, 50010
McFarland Clinic PC - Ames
Ames, Iowa, 50010
AnMed Health Cancer Center
Anderson, South Carolina, 29621
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106
Langlade Hospital and Cancer Center
Antigo, Wisconsin, 54409
John Fitzgerald Kennedy Medical Center
Atlantis, Florida, 33462
Rush - Copley Medical Center
Aurora, Illinois, 60504
Mount Sinai Comprehensive Cancer Center at Aventura
Aventura, Florida, 33180
McLaren Cancer Institute-Bay City
Bay City, Michigan, 48706
Strecker Cancer Center-Belpre
Belpre, Ohio, 45714
Billings Clinic Cancer Center
Billings, Montana, 59101
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
Prisma Health Cancer Institute - Spartanburg
Boiling Springs, South Carolina, 29316
McFarland Clinic PC-Boone
Boone, Iowa, 50036
Lafayette Family Cancer Center-EMMC
Brewer, Maine, 04412
IHA Hematology Oncology Consultants-Brighton
Brighton, Michigan, 48114
Saint Joseph Mercy Brighton
Brighton, Michigan, 48114
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Cambridge Medical Center
Cambridge, Minnesota, 55008
Illinois CancerCare-Canton
Canton, Illinois, 61520
IHA Hematology Oncology Consultants-Canton
Canton, Michigan, 48188
Saint Joseph Mercy Canton
Canton, Michigan, 48188
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Centralia Oncology Clinic
Centralia, Illinois, 62801
IHA Hematology Oncology Consultants-Chelsea
Chelsea, Michigan, 48118
Saint Joseph Mercy Chelsea
Chelsea, Michigan, 48118
Northwestern University
Chicago, Illinois, 60611
Marshfield Clinic-Chippewa Center
Chippewa Falls, Wisconsin, 54729
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, Ohio, 45219
McLaren Cancer Institute-Clarkston
Clarkston, Michigan, 48346
Mount Carmel East Hospital
Columbus, Ohio, 43213
Columbus Oncology and Hematology Associates Inc
Columbus, Ohio, 43214
The Mark H Zangmeister Center
Columbus, Ohio, 43219
Mount Carmel Health Center West
Columbus, Ohio, 43222
Mercy Hospital
Coon Rapids, Minnesota, 55433
UC Irvine Health Cancer Center-Newport
Costa Mesa, California, 92627
Carle on Vermilion
Danville, Illinois, 61832
Beaumont Hospital - Dearborn
Dearborn, Michigan, 48124
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, 62526
Decatur Memorial Hospital
Decatur, Illinois, 62526
Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates-Des Moines
Des Moines, Iowa, 50309
Broadlawns Medical Center
Des Moines, Iowa, 50314
Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, 48201
Ascension Saint John Hospital
Detroit, Michigan, 48236
Illinois CancerCare-Dixon
Dixon, Illinois, 61021
City of Hope Comprehensive Cancer Center
Duarte, California, 91010
Great Lakes Cancer Management Specialists-Doctors Park
East China Township, Michigan, 48054
Marshfield Medical Center-EC Cancer Center
Eau Claire, Wisconsin, 54701
Fairview Southdale Hospital
Edina, Minnesota, 55435
Carle Physician Group-Effingham
Effingham, Illinois, 62401
Crossroads Cancer Center
Effingham, Illinois, 62401
Illinois CancerCare-Eureka
Eureka, Illinois, 61530
Parkland Health Center - Farmington
Farmington, Missouri, 63640
Weisberg Cancer Treatment Center
Farmington Hills, Michigan, 48334
Beaumont Hospital - Farmington Hills
Farmington Hills, Michigan, 48336
McLaren Cancer Institute-Flint
Flint, Michigan, 48532
Singh and Arora Hematology Oncology PC
Flint, Michigan, 48532
McFarland Clinic PC-Trinity Cancer Center
Fort Dodge, Iowa, 50501
Beebe South Coastal Health Campus
Frankford, Delaware, 19945
Unity Hospital
Fridley, Minnesota, 55432
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
Western Illinois Cancer Treatment Center
Galesburg, Illinois, 61401
Prisma Health Cancer Institute - Butternut
Greenville, South Carolina, 29605
Prisma Health Cancer Institute - Faris
Greenville, South Carolina, 29605
Prisma Health Cancer Institute - Eastside
Greenville, South Carolina, 29615
Prisma Health Cancer Institute - Greer
Greer, South Carolina, 29650
Academic Hematology Oncology Specialists
Grosse Pointe Woods, Michigan, 48236
Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
Grosse Pointe Woods, Michigan, 48236
Michigan Breast Specialists-Grosse Pointe Woods
Grosse Pointe Woods, Michigan, 48236
Mount Carmel Grove City Hospital
Grove City, Ohio, 43123
HaysMed University of Kansas Health System
Hays, Kansas, 67601
Comprehensive Cancer Centers of Nevada - Henderson
Henderson, Nevada, 89052
OptumCare Cancer Care at Seven Hills
Henderson, Nevada, 89052
Comprehensive Cancer Centers of Nevada-Southeast Henderson
Henderson, Nevada, 89074
Las Vegas Urology - Green Valley
Henderson, Nevada, 89074
Las Vegas Urology - Pebble
Henderson, Nevada, 89074
Urology Specialists of Nevada - Green Valley
Henderson, Nevada, 89074
Hawaii Cancer Care Inc - Waterfront Plaza
Honolulu, Hawaii, 96813
Queen's Cancer Cenrer - POB I
Honolulu, Hawaii, 96813
Queen's Medical Center
Honolulu, Hawaii, 96813
Straub Clinic and Hospital
Honolulu, Hawaii, 96813
University of Hawaii Cancer Center
Honolulu, Hawaii, 96813
Hawaii Cancer Care Inc-Liliha
Honolulu, Hawaii, 96817
Queen's Cancer Center - Kuakini
Honolulu, Hawaii, 96817
The Cancer Center of Hawaii-Liliha
Honolulu, Hawaii, 96817
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, 96826
M D Anderson Cancer Center
Houston, Texas, 77030
McFarland Clinic PC-Jefferson
Jefferson, Iowa, 50129
University of Kansas Cancer Center-West
Kansas City, Kansas, 66112
University of Kansas Cancer Center
Kansas City, Kansas, 66160
Truman Medical Centers
Kansas City, Missouri, 64108
University of Kansas Cancer Center - North
Kansas City, Missouri, 64154
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Marshfield Clinic - Ladysmith Center
Ladysmith, Wisconsin, 54848
McLaren-Greater Lansing
Lansing, Michigan, 48910
Mid-Michigan Physicians-Lansing
Lansing, Michigan, 48912
McLaren Cancer Institute-Lapeer Region
Lapeer, Michigan, 48446
Las Vegas Urology - Pecos
Las Vegas, Nevada, 89074
OptumCare Cancer Care at Charleston
Las Vegas, Nevada, 89102
Hope Cancer Care of Nevada
Las Vegas, Nevada, 89103
Radiation Oncology Centers of Nevada Central
Las Vegas, Nevada, 89106
Urology Specialists of Nevada - Central
Las Vegas, Nevada, 89106
Las Vegas Urology - Sunset
Las Vegas, Nevada, 89113
Urology Specialists of Nevada - Southwest
Las Vegas, Nevada, 89113
Comprehensive Cancer Centers of Nevada - Northwest
Las Vegas, Nevada, 89128
Las Vegas Urology - Cathedral Rock
Las Vegas, Nevada, 89128
Las Vegas Urology - Smoke Ranch
Las Vegas, Nevada, 89128
OptumCare Cancer Care at MountainView
Las Vegas, Nevada, 89128
Urology Specialists of Nevada - Northwest
Las Vegas, Nevada, 89128
Comprehensive Cancer Centers of Nevada-Summerlin
Las Vegas, Nevada, 89144
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89148
OptumCare Cancer Care at Fort Apache
Las Vegas, Nevada, 89148
Comprehensive Cancer Centers of Nevada - Central Valley
Las Vegas, Nevada, 89169
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Cancer Centers of Southwest Oklahoma Research
Lawton, Oklahoma, 73505
University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri, 64064
Saint Joseph Regional Medical Center
Lewiston, Idaho, 83501
Wilcox Memorial Hospital and Kauai Medical Clinic
Lihue, Hawaii, 96766
Hope Cancer Clinic
Livonia, Michigan, 48154
Saint Mary Mercy Hospital
Livonia, Michigan, 48154
Illinois CancerCare-Macomb
Macomb, Illinois, 61455
Great Lakes Cancer Management Specialists-Macomb Medical Campus
Macomb, Michigan, 48044
Fairview Clinics and Surgery Center Maple Grove
Maple Grove, Minnesota, 55369
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Saint John's Hospital - Healtheast
Maplewood, Minnesota, 55109
Marietta Memorial Hospital
Marietta, Ohio, 45750
McFarland Clinic PC-Marshalltown
Marshalltown, Iowa, 50158
Marshfield Medical Center-Marshfield
Marshfield, Wisconsin, 54449
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois, 61938
Aspirus Medford Hospital
Medford, Wisconsin, 54451
Mount Sinai Medical Center
Miami Beach, Florida, 33140
Mid-Michigan Medical Center - Midland
Midland, Michigan, 48670
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Health Partners Inc
Minneapolis, Minnesota, 55454
Marshfield Clinic-Minocqua Center
Minocqua, Wisconsin, 54548
McLaren Cancer Institute-Central Michigan
Mount Pleasant, Michigan, 48858
Skagit Valley Hospital Regional Cancer Care Center
Mount Vernon, Washington, 98274
Cancer Center of Western Wisconsin
New Richmond, Wisconsin, 54017
New Ulm Medical Center
New Ulm, Minnesota, 56073
Helen F Graham Cancer Center
Newark, Delaware, 19713
Medical Oncology Hematology Consultants PA
Newark, Delaware, 19713
University of Kansas Cancer Center at North Kansas City Hospital
North Kansas City, Missouri, 64116
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Olathe Health Cancer Center
Olathe, Kansas, 66061
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868
Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois, 61350
University of Kansas Cancer Center-Overland Park
Overland Park, Kansas, 66210
University of Kansas Hospital-Indian Creek Campus
Overland Park, Kansas, 66211
Illinois CancerCare-Pekin
Pekin, Illinois, 61554
Illinois CancerCare-Peoria
Peoria, Illinois, 61615
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
Illinois CancerCare-Peru
Peru, Illinois, 61354
McLaren Cancer Institute-Northern Michigan
Petoskey, Michigan, 49770
McLaren-Port Huron
Port Huron, Michigan, 48060
Maine Medical Partners Surgical Care
Portland, Maine, 04102
MMP Surgical Care Casco Bay
Portland, Maine, 04102
Illinois CancerCare-Princeton
Princeton, Illinois, 61356
Beebe Health Campus
Rehoboth Beach, Delaware, 19971
Marshfield Medical Center-Rice Lake
Rice Lake, Wisconsin, 54868
Virginia Cancer Institute
Richmond, Virginia, 23230
VCU Massey Cancer Center at Stony Point
Richmond, Virginia, 23235
Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, 23298
North Memorial Medical Health Center
Robbinsdale, Minnesota, 55422
Great Lakes Cancer Management Specialists-Rochester Hills
Rochester Hills, Michigan, 48309
William Beaumont Hospital-Royal Oak
Royal Oak, Michigan, 48073
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota, 55416
Regions Hospital
Saint Paul, Minnesota, 55101
United Hospital
Saint Paul, Minnesota, 55102
Sainte Genevieve County Memorial Hospital
Sainte Genevieve, Missouri, 63670
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229
Virginia Mason Medical Center
Seattle, Washington, 98101
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109
Seattle Cancer Care Alliance
Seattle, Washington, 98109
University of Washington Medical Center - Montlake
Seattle, Washington, 98195
Prisma Health Cancer Institute - Seneca
Seneca, South Carolina, 29672
Olympic Medical Cancer Care Center
Sequim, Washington, 98384
Saint Francis Regional Medical Center
Shakopee, Minnesota, 55379
VCU Community Memorial Health Center
South Hill, Virginia, 23970
Southern Illinois University School of Medicine
Springfield, Illinois, 62702
Springfield Clinic
Springfield, Illinois, 62702
Memorial Medical Center
Springfield, Illinois, 62781
Missouri Baptist Medical Center
St Louis, Missouri, 63131
Marshfield Clinic Stevens Point Center
Stevens Point, Wisconsin, 54482
Lakeview Hospital
Stillwater, Minnesota, 55082
Missouri Baptist Sullivan Hospital
Sullivan, Missouri, 63080
Missouri Baptist Outpatient Center-Sunset Hills
Sunset Hills, Missouri, 63127
William Beaumont Hospital - Troy
Troy, Michigan, 48085
Banner University Medical Center - Tucson
Tucson, Arizona, 85719
University of Arizona Cancer Center-North Campus
Tucson, Arizona, 85719
Carle Cancer Center
Urbana, Illinois, 61801
The Carle Foundation Hospital
Urbana, Illinois, 61801
Ridgeview Medical Center
Waconia, Minnesota, 55387
Great Lakes Cancer Management Specialists-Macomb Professional Building
Warren, Michigan, 48093
Saint John Macomb-Oakland Hospital
Warren, Michigan, 48093
Aspirus Regional Cancer Center
Wausau, Wisconsin, 54401
Marshfield Clinic-Wausau Center
Wausau, Wisconsin, 54401
Wenatchee Valley Hospital and Clinics
Wenatchee, Washington, 98801
University of Cincinnati Cancer Center-West Chester
West Chester, Ohio, 45069
Methodist West Hospital
West Des Moines, Iowa, 50266-7700
Saint Ann's Hospital
Westerville, Ohio, 43081
Marshfield Medical Center - Weston
Weston, Wisconsin, 54476
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, 66205
Presbyterian Intercommunity Hospital
Whittier, California, 90602
Rice Memorial Hospital
Willmar, Minnesota, 56201
Asplundh Cancer Pavilion
Willow Grove, Pennsylvania, 19090
Shenandoah Oncology PC
Winchester, Virginia, 22601
Valley Health / Winchester Medical Center
Winchester, Virginia, 22601
Aspirus Cancer Care - Wisconsin Rapids
Wisconsin Rapids, Wisconsin, 54494
Marshfield Clinic - Wisconsin Rapids Center
Wisconsin Rapids, Wisconsin, 54494
Minnesota Oncology Hematology PA-Woodbury
Woodbury, Minnesota, 55125
Fairview Lakes Medical Center
Wyoming, Minnesota, 55092
Rush-Copley Healthcare Center
Yorkville, Illinois, 60560
Huron Gastroenterology PC
Ypsilanti, Michigan, 48106
IHA Hematology Oncology Consultants-Ann Arbor
Ypsilanti, Michigan, 48197
About this study
Official title: A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)
This phase II trial studies how a diet intervention works in improving bowel dysfunction symptoms related in colon or rectal cancer survivors. Changing a diet may be helpful in reducing the severity of bowel symptoms, including diarrhea and constipation, and improve quality of life in colon or rectal cancer survivors and help doctors learn how to help patients better in the future.
Read the detailed description
PRIMARY OBJECTIVES:
- To compare total bowel function score, as measured by the Memorial Sloan-Kettering Cancer Center Bowel Function Instrument (BFI), at 18 weeks post-randomization between the intervention and attention control arms.
EXPLORATORY OBJECTIVES:
- To compare total bowel function score at 26 weeks post-randomization between the intervention and attention control arms.
II. To compare bowel function subscale scores (dietary, urgency, frequency), as measured by the BFI at both 18- and 26- weeks post-randomization between the intervention and attention control arms.
III. To compare lower anterior resection syndrome (LARS) scores (for anastomosis participants only), quality of life, and dietary quality at both 18- and 26- weeks post-randomization between the intervention and attention control arms.
IV. To compare motivation, self-efficacy, and positive/negative affect at both 18- and 26- weeks post-randomization between the intervention and attention control arms.
- To assess study feasibility, adherence, retention, and acceptability at both 18 and 26 weeks post-randomization.
VI. To explore variation in primary and exploratory study outcomes according to sex, and to investigate whether intervention effects on the primary outcome differ across subgroups defined by sex.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive diet modification coaching via telephone for 10 sessions over 30-60 minutes over 17 weeks. Patients also receive 3 motivational messages per week via email and/or text message beginning after session 6.
ARM II: Patients receive general healthy living education via telephone for 10 sessions over 30-60 minutes over 17 weeks. Patients also receive 3 motivational messages per week via email and/or text message beginning after session 6.
After completion of study, patients are followed up at 26 weeks.
- Conditions
- Rectal Carcinoma, Rectosigmoid Carcinoma
- Being tested
- Best Practice, Dietary Intervention, Message, Quality-of-Life Assessment, Questionnaire Administration
- Medical subject headings
- Rectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Best PracticeOther
Also called standard of care, standard therapy
Receive healthy living education via phone call
Dietary InterventionDietary supplement
Also called Dietary Modification, intervention, dietary, Nutrition Intervention, Nutrition Interventions
Receive diet modification coaching via phone call
MessageOther
Receive motivational messages via email and/or text message
Quality-of-Life AssessmentOther
Also called Quality of Life Assessment
Ancillary studies
Questionnaire AdministrationOther
Ancillary studies
| Study group | Role | What they receive |
|---|---|---|
| Arm I (diet modification coaching, motivational messages) | Experimental | Patients receive diet modification coaching via telephone for 10 sessions over 30-60 minutes over 17 weeks. Patients also receive 3 motivational messages per week via email and/or text message beginning after session 6. Receives: Dietary Supplement: Dietary Intervention; Other: Message; Other: Quality-of-Life Assessment; Other: Questionnaire Administration |
| Arm II (standard of care, motivational messages) | Active comparator | Patients receive general healthy living education via telephone for 10 sessions over 30-60 minutes over 17 weeks. Patients also receive 3 motivational messages per week via email and/or text message beginning after session 6. Receives: Other: Best Practice; Other: Message; Other: Quality-of-Life Assessment; Other: Questionnaire Administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Bowel Function
Will be measured by the Memorial Sloan-Kettering Cancer Center Bowel Function Instrument (BFI) total score. Score range 18-90. Higher scores indicate better bowel function. Will be conducted according to a modified intention-to-treat principle. Study arm differences in BFI at 18 weeks will be assessed by a linear regression model as a function of randomization assignment, BFI baseline value, and stratification factors.
Measured: At 18 weeks after randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Dec 2019
- Study start10 Feb 2020
- Primary completion1 Apr 2023
- Study completion1 Aug 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Rectal CarcinomaStudies of the same condition, open and under way.
- More trials run by SWOG Cancer Research NetworkThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 95 participants (actual)
Sponsor and investigators
- Lead sponsor
- SWOG Cancer Research Network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Virginia Sun, Principal investigator, SWOG Cancer Research Network
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04205955
- Sponsor's protocol ID
- S1820
- Other IDs
- NCI-2019-04990, S1820, SWOG-S1820, S1820, R21CA236057, UG1CA189974
- Status last verified
- Apr 2024
- First submitted
- 18 Dec 2019
- Last updated
- 1 May 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 May 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)
- ClinicalTrials.gov ID
- NCT04205955
- Acronym / sponsor ID
- S1820
- Conditions
- Rectal Carcinoma, Rectosigmoid Carcinoma
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 95 participants (actual)
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 10 Feb 2020 (actual)
- Primary completion
- 1 Apr 2023 (actual)
- Study completion
- 1 Aug 2023 (actual)
- First posted
- 20 Dec 2019 (actual)
- Results
- Posted 1 May 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This phase II trial studies how a diet intervention works in improving bowel dysfunction symptoms related in colon or rectal cancer survivors. Changing a diet may be helpful in reducing the severity of bowel symptoms, including diarrhea and constipation, and improve quality of life in colon or rectal cancer survivors and help doctors learn how to help patients better in the future.
Detailed description
PRIMARY OBJECTIVES:
- To compare total bowel function score, as measured by the Memorial Sloan-Kettering Cancer Center Bowel Function Instrument (BFI), at 18 weeks post-randomization between the intervention and attention control arms.
EXPLORATORY OBJECTIVES:
- To compare total bowel function score at 26 weeks post-randomization between the intervention and attention control arms.
II. To compare bowel function subscale scores (dietary, urgency, frequency), as measured by the BFI at both 18- and 26- weeks post-randomization between the intervention and attention control arms.
III. To compare lower anterior resection syndrome (LARS) scores (for anastomosis participants only), quality of life, and dietary quality at both 18- and 26- weeks post-randomization between the intervention and attention control arms.
IV. To compare motivation, self-efficacy, and positive/negative affect at both 18- and 26- weeks post-randomization between the intervention and attention control arms.
- To assess study feasibility, adherence, retention, and acceptability at both 18 and 26 weeks post-randomization.
VI. To explore variation in primary and exploratory study outcomes according to sex, and to investigate whether intervention effects on the primary outcome differ across subgroups defined by sex.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive diet modification coaching via telephone for 10 sessions over 30-60 minutes over 17 weeks. Patients also receive 3 motivational messages per week via email and/or text message beginning after session 6.
ARM II: Patients receive general healthy living education via telephone for 10 sessions over 30-60 minutes over 17 weeks. Patients also receive 3 motivational messages per week via email and/or text message beginning after session 6.
After completion of study, patients are followed up at 26 weeks.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm I (diet modification coaching, motivational messages) | Experimental | Dietary Supplement: Dietary Intervention, Other: Message, Other: Quality-of-Life Assessment, Other: Questionnaire AdministrationPatients receive diet modification coaching via telephone for 10 sessions over 30-60 minutes over 17 weeks. Patients also receive 3 motivational messages per week via email and/or text message beginning after session 6. |
| Arm II (standard of care, motivational messages) | Active comparator | Other: Best Practice, Other: Message, Other: Quality-of-Life Assessment, Other: Questionnaire AdministrationPatients receive general healthy living education via telephone for 10 sessions over 30-60 minutes over 17 weeks. Patients also receive 3 motivational messages per week via email and/or text message beginning after session 6. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (16 listed)
- PRIOR TO STEP 1 REGISTRATION:
- Patients must have prior history of rectosigmoid colon cancer or rectal cancer
- Patients must have a post-surgical permanent ostomy or anastomosis
- Patient's last date of treatment for rectal cancer (any surgery, chemotherapy, radiation therapy) must be at least 6 months prior to registration and not more than 24 months prior to registration
- Anastomosis patients must have low anterior resection syndrome (LARS) score of 21-42 (minor to major symptoms) within 5 calendar days prior to registration
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Best PracticeAlso: standard of care, standard therapyReceive healthy living education via phone call | Other | Arm II (standard of care, motivational messages) |
| Dietary InterventionAlso: Dietary Modification, intervention, dietary, Nutrition Intervention, Nutrition InterventionsReceive diet modification coaching via phone call | Dietary supplement | Arm I (diet modification coaching, motivational messages) |
| MessageReceive motivational messages via email and/or text message | Other | Arm I (diet modification coaching, motivational messages), Arm II (standard of care, motivational messages) |
| Quality-of-Life AssessmentAlso: Quality of Life AssessmentAncillary studies | Other | Arm I (diet modification coaching, motivational messages), Arm II (standard of care, motivational messages) |
| Questionnaire AdministrationAncillary studies | Other | Arm I (diet modification coaching, motivational messages), Arm II (standard of care, motivational messages) |
Primary outcome
Bowel Function
Time frame: At 18 weeks after randomization
Will be measured by the Memorial Sloan-Kettering Cancer Center Bowel Function Instrument (BFI) total score. Score range 18-90. Higher scores indicate better bowel function. Will be conducted according to a modified intention-to-treat principle. Study arm differences in BFI at 18 weeks will be assessed by a linear regression model as a function of randomization assignment, BFI baseline value, and stratification factors.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 May 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Rectal Carcinoma
RecruitingPhase 1
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Solid Tumor, Non-Small-Cell Lung Cancer
Not yet recruitingObservational study
Cohort Study to eLucidAte Causes, Behaviour and Outcomes of gastRo Intestinal Tract Cancers in the Young
Colorectal Cancer, Gastro-oesophageal Adenocarcinoma
RecruitingObservational study
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
Colorectal Neoplasms, Gastric Neoplasms
RecruitingPhase 1/2
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
Solid Tumor, NSCLC
Not yet recruitingPhase 2
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy Combined With Penpulimab and Fruquintinib for Advanced Colorectal Cancer
Colo-rectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Virginia Sun principal investigator
SWOG Cancer Research Network
226 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Best Practice, Dietary Intervention and Message in people with Rectal Carcinoma and Rectosigmoid Carcinoma, run by SWOG Cancer Research Network at 226 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 16 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 May 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 226 sites in United States, Guam. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 1 May 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Bowel Function (time frame: At 18 weeks after randomization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2024.